Charles River Laboratories International, Inc. (NYSE:CRL) Position Trimmed by Raymond James & Associates

Raymond James & Associates trimmed its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 3.4% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 243,688 shares of the medical research company’s stock after selling 8,488 shares during the period. Raymond James & Associates owned about 0.48% of Charles River Laboratories International worth $57,608,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in CRL. Moneta Group Investment Advisors LLC purchased a new stake in shares of Charles River Laboratories International in the 4th quarter valued at approximately $298,877,000. Meritage Group LP purchased a new stake in shares of Charles River Laboratories International in the 3rd quarter valued at approximately $173,174,000. Price T Rowe Associates Inc. MD lifted its position in shares of Charles River Laboratories International by 35.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,506,293 shares of the medical research company’s stock valued at $505,821,000 after acquiring an additional 653,790 shares in the last quarter. Norges Bank purchased a new stake in shares of Charles River Laboratories International in the 4th quarter valued at approximately $97,675,000. Finally, BlackRock Inc. lifted its position in shares of Charles River Laboratories International by 8.6% in the 2nd quarter. BlackRock Inc. now owns 5,198,037 shares of the medical research company’s stock valued at $1,092,887,000 after acquiring an additional 411,153 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on CRL shares. Citigroup increased their target price on shares of Charles River Laboratories International from $215.00 to $250.00 and gave the stock a “neutral” rating in a research report on Thursday, February 15th. Argus increased their target price on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the stock a “buy” rating in a research report on Monday, March 18th. Robert W. Baird increased their target price on shares of Charles River Laboratories International from $252.00 to $268.00 and gave the stock an “outperform” rating in a research report on Thursday, February 15th. JPMorgan Chase & Co. increased their target price on shares of Charles River Laboratories International from $270.00 to $280.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. Finally, UBS Group increased their target price on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the stock a “buy” rating in a research report on Thursday, February 15th. Six research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and a consensus price target of $249.64.

Insiders Place Their Bets

In other Charles River Laboratories International news, VP William D. Barbo sold 4,050 shares of the firm’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total value of $1,006,425.00. Following the sale, the vice president now directly owns 22,879 shares in the company, valued at approximately $5,685,431.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Charles River Laboratories International news, VP William D. Barbo sold 4,050 shares of the firm’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total value of $1,006,425.00. Following the sale, the vice president now directly owns 22,879 shares in the company, valued at approximately $5,685,431.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Shannon M. Parisotto sold 5,882 shares of the firm’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the sale, the executive vice president now owns 2,596 shares in the company, valued at $626,155.20. The disclosure for this sale can be found here. Insiders have sold 14,932 shares of company stock worth $3,693,663 in the last ninety days. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $269.37 on Thursday. Charles River Laboratories International, Inc. has a 12 month low of $161.65 and a 12 month high of $275.00. The company’s fifty day moving average is $242.91 and its 200-day moving average is $215.59. The company has a quick ratio of 1.16, a current ratio of 1.52 and a debt-to-equity ratio of 0.73. The firm has a market cap of $13.82 billion, a price-to-earnings ratio of 29.25, a price-to-earnings-growth ratio of 2.08 and a beta of 1.39.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, February 14th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.39 by $0.07. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $991.25 million. During the same period last year, the business posted $2.98 EPS. Charles River Laboratories International’s revenue was down 7.9% compared to the same quarter last year. Equities analysts expect that Charles River Laboratories International, Inc. will post 11.01 EPS for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).